Category: AI drug development

  • BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone

    BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the London-based research firm. This is the third novel target from the duo’s collaboration identified using the Benevolent Platform across two disease areas – IPF and chronic kidney […]

  • Digital health companies enabling R&D topped 2021 US investment, Rock Health says

    According to Rock Health’s annual digital health funding report, US-based digital health companies enabling life sciences research and development raised $5.8 billion (£4.3 billion) in 2021, making it the top funded category of the sector. This is the first time R&D has topped the chart since Rock Health began tracking US digital health funding in […]